I don't expect bad news in the 10Q, only news that
Post# of 72440
Seeing that we have access to funds now that should be able to pay the CRO, I can only surmise that mgt has decided they may have access to much cheaper funds in the near future and thus aren't using the MFO funds to pay the CRO.
As such, I don't see the 10Q providing a whole lot of new information as all the important stuff is in the negotiations, FDA decisions, and further progress as to trials (sachet progress, pill progress, etc) and all the above shouldn't have had much movement prior to October.
The news announcements are the real deal that will move the stock and the partnership announcement is the only news that will move the stock and keep it at levels way above today IMO.
Still patiently waiting.